Receptor News and Research

RSS

New molecular interaction governs formation of specific connections between neurons

Researchers at VIB and KU Leuven have uncovered a new molecular interaction that governs the formation of specific functional connections between two types of neurons.

3 Oct 2018

Researchers find ALS drug as potential treatment for prostate cancer

Researchers have discovered a new use for an old drug as a potential treatment for prostate cancer. The findings are published in the journal The Prostate.

3 Oct 2018

Study identifies camelid nanobodies capable of blocking EGF in cancer cells

The natural world often provides the answer to unsolved medical problems. On this occasion, the solution to a challenge posed by cancer has come about from the immune system of camelids.

3 Oct 2018

Immune protein 'flutters' like a butterfly in search of viruses, finds study

Researchers at Rutgers Robert Wood Johnson Medical School have identified an important step in the process that allows our bodies to fight viruses.

2 Oct 2018

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Why patients with ALL relapse after CAR-T cell therapy

Researchers have made a new discovery about a rare mechanism that triggers the relapse of acute lymphoblastic leukemia (ALL) after CAR T cell therapy.

1 Oct 2018

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. received approval from the U.S. Food and Drug Administration for an indication expansion for Eisai's antiepileptic drug Fycompa (perampanel) to cover partial-onset seizures in pediatric patients with epilepsy 4 years of age and older.

1 Oct 2018

UB receives £1.78 million to find new therapies for treating heart failure and diabetes

The University of Birmingham has been awarded £1.78 million by the Wellcome Trust for research aimed at finding new therapies to treat diseases such as heart failure, diabetes and neurodegenerative disorders.

29 Sep 2018

New tool provides improved in vivo imaging of atherosclerotic plaque development

Atherosclerosis, involving the buildup of plaque in the arteries and an associated reduction in the flow of blood, is a major feature of cardiovascular diseases.

28 Sep 2018

Common biomarker of kidney disease may also indicate COPD

A commonly used biomarker of kidney disease may also indicate lung problems, particularly COPD, or chronic obstructive pulmonary disease, according to new research published online in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

28 Sep 2018

Loyola announces plans to produce CAR-T cells for treating cancer

Loyola University Chicago and Loyola Medicine have announced plans to become the first Chicago center to produce cancer-fighting CAR-T cells to treat leukemia and lymphoma.

28 Sep 2018

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Verastem OncologyTM to dispense COPIKTRA (duvelisib) capsules.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

Breastfeeding changes gene activity that regulates infant's response to stress

It has long been known that there are many physical and mental health benefits of breastfeeding for mothers and babies. But can these benefits be due to genetic changes induced by breastfeeding? New research suggests that connection.

27 Sep 2018

New compound promotes social interaction in laboratory mice with autism

Children with autism often find social interactions awkward, leaving them isolated. Now in a study appearing in ACS' Journal of Medicinal Chemistry, scientists report that they have discovered a first-of-its-kind compound that promotes social interaction among laboratory mice that display autistic traits.

26 Sep 2018

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make informed decisions on how to sequence treatments for patients with epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC).

26 Sep 2018

Researchers discover novel targeting agents to prevent cancer metastasis

Recently, a research team led by Maurizio Pellecchia at the University of California, Riverside, discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

26 Sep 2018

Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease

Cerevance, a clinical-stage drug discovery and development company focused on brain diseases, today announced the start of dosing in a Phase I first-in-human clinical trial of CVN424, an oral compound being developed for symptomatic treatment of Parkinson's disease.

25 Sep 2018

Environmentally-induced gene activity influences IQ test performance

Is there a link between differences in IQ test performance and the activity of certain genes? Researchers from Charité - Universitätsmedizin Berlin have shown that modifications in the structure of a specific gene have a negative impact on individual test performance.

25 Sep 2018

Receptor News and Research

New molecular interaction governs formation of specific connections between neurons

Researchers find ALS drug as potential treatment for prostate cancer

Study identifies camelid nanobodies capable of blocking EGF in cancer cells

Immune protein 'flutters' like a butterfly in search of viruses, finds study

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Eisai's antiepileptic drug receives FDA approval to treat partial-onset seizures in pediatric patients

UB receives £1.78 million to find new therapies for treating heart failure and diabetes

New tool provides improved in vivo imaging of atherosclerotic plaque development

Common biomarker of kidney disease may also indicate COPD

Loyola announces plans to produce CAR-T cells for treating cancer

Verastem Oncology selects US Bioservices to dispense COPIKTRA capsules

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

Breastfeeding changes gene activity that regulates infant's response to stress

New compound promotes social interaction in laboratory mice with autism

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Researchers discover novel targeting agents to prevent cancer metastasis

Cerevance starts dosing in Phase I clinical trial of CVN424 for treatment of Parkinson's disease

Environmentally-induced gene activity influences IQ test performance

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News